TriSalus Life Sciences forecasts $54M-$57M in Q1 2026 revenue as TriNav Advance clearance faces a five-month delay.
TriSalus Life Sciences (TLSI) outlined a Q1 2026 revenue forecast of $54M-$57M during its earnings call. The projection reflects ongoing commercial efforts despite a regulatory setback for its TriNav Advance device, which received clearance approximately five months later than targeted.
The company previously guided for accelerated growth in 2026, citing expanding market adoption. Analysts had anticipated revenue near the midpoint of the range, though delays in product clearance may temper near-term expectations.
Shares showed muted reaction in after-hours trading as investors weighed the revenue outlook against regulatory challenges.